Oak Brook Terrace, IL, [January. 7, 2025] — Visible Genomics, a leading provider of genetic testing solutions for severe ocular diseases, has been named Life Sciences Review AMD Genetic Testing Company of the Year 2025. This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degeneration (AMD), a leading cause of blindness in the U.S.

Visible Genomics is transforming the landscape of eye care by redefining how AMD risk factors are evaluated and addressed. Recognizing that genetics may account for up to 70 percent of the chance of developing advanced AMD, the company’s proprietary AMD genetic tests are empowering eye care professionals with a deeper understanding of a patient’s unique genetic risk, enabling earlier interventions and personalized treatment strategies.

“We are thrilled to be recognized for our commitment to advancing preventative eye care,” said Scott Rediger, CEO of Visible Genomics. “By leveraging the power of genetics, we can identify individuals at risk for AMD early on, allowing for timely interventions and potentially mitigating vision loss before it becomes irreversible.”

The company’s flagship products are the AMDiGuard™ lifetime test and AMDiGuard™ progression test. The lifetime test facilitates early awareness for individuals that are at high genetic risk but do not show signs or symptoms of AMD, while the progression test analyzes the risk of advanced AMD in patients who are already in the early or intermediate stages of the disease. Both tests aim to help prevent irreversible vision loss.

The AMDiGuard tests utilize a simple cheek swab to collect DNA, and samples are processed in a CLIA-certified laboratory, ensuring accurate and reliable results. Results are digitally delivered to eye care professionals in a HIPAA-compliant format for evaluation. The doctor/ patient consultation is part of the design of a personalized health and wellness plan to delay potential onset or slow progression of advanced AMD.

Visible Genomics is committed to making its genetic tests accessible. The company is partnering with medical education providers and academic institutions to integrate genomic insights into professional training and practice.

About Visible Genomics:

Visible Genomics is a pioneering genetics’ testing and risk assessment company with a focus on severe ocular diseases. At the forefront of personalized eyecare, Visible Genomics offers a proactive approach to protecting vision for millions of people at risk of developing advanced AMD.

For a comprehensive understanding of Visible Genomics’ impact on preventative care, read “Unlocking Proactive Care with Genetic Testing” in the Life Sciences Award feature: [Click Here]

Learn more about the company here: www.visiblegenomics.com.